REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of One Nitrogen And Five Carbon Atoms > Polycyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos > Tricyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos > Plural Hetero Atoms In The Tricyclo Ring System Plural Hetero Atoms In The Tricyclo Ring SystemPlural Hetero Atoms In The Tricyclo Ring System patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027178 - Substituted tetrahydro-1h-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation ... 02/01/07 - 20070027177 - Isoquinolinone potassium channel inhibitors The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like. ... 01/25/07 - 20070021456 - Aminobenzimidazole derivatives Novel compounds of formula (I) are disclosed, where R1, R1′, L, Y, m and p have the meanings given in claim 1, which are inhibitors of tyrosine kinases, in particular, TIE-2 and Raf kinases and can be used for the treatment of tumors. ... 01/18/07 - 20070015785 - Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament The invention relates to a crystalline micronisate of (1 α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity. ... 01/11/07 - 20070010547 - Method for modulating gene expression in epithelial cells The present invention is directed to methods for modulating gene expression in an epithelial cell. ... 01/11/07 - 20070010546 - Method for enhancing epithelial cell proliferation and uses thereof The present invention is directed to uses of GM-284 for enhancing epithelial cell proliferation. The present invention is also provides methods for treating a keratinocyte-associated disorder in a subject in need of treatment. ... 01/11/07 - 20070010545 - Solid forms of a chemokine receptor antagonist and methods of use thereof The citrate salt of (S)-4-(4-Chloro-phenyl)-1-{3-[7-(1-hydroxy-1-methyl-ethyl)-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene]-propyl}-3,3-dimethyl-piperidin-4-ol, which may be used in pharmaceutical applications, is disclosed. The crystalline Citrate Salt, including particular single crystal forms and combinations of the single crystalline forms, are also discussed. Mixtures for forming the crystalline salts are discussed. As well, methods of producing the Citrate Salt, and ... 01/04/07 - 20070004767 - Methods for treating neurofibromatosis 1 This invention is directed generally to methods for treating neurofibromatosis 1 (NF1), and, more particularly, to methods for treating NF1 by administering rapamycin, a rapamycin analog, a rapamycin prodrug, or a salt of rapamycin or the analog or prodrug. This invention also is directed generally to compositions and kits for ... 12/21/06 - 20060287353 - Method for preventing or treating ischemia-or hemorrhage-induced brain damage using a macrolide compound Macrolide compound, such as a tacrolimus analogue is provided for use as a neuroprotective agent, particularly, for preventing or treating acute or chronic cerebral neurodegenerative diseases. ... 12/21/06 - 20060287352 - Modified release compositions comprising tacrolimus A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects ... 12/07/06 - 20060276497 - Novel multicyclic compounds and the use thereof The present invention is directed to novel multicyclic molecules that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of PARP, VEGFR2, and MLK3 enzymes, including, for example, neurodegenerative diseases, inflammation, ischemia, and cancer. ... 12/07/06 - 20060276496 - Anti-cytokine heterocyclic compounds Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and ... 11/30/06 - 20060270699 - Stabilization of hypoxia inducible factor (hif) alpha The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided. ... 11/30/06 - 20060270698 - Scopolamine for the treatment of depression and anxiety Provided herein are methods and compositions for the treatment of depression and anxiety. The compositions comprise scopolamine, or an analog thereof, and can optionally include one or more psychoactive agents. Further provided is an inhaler comprising scopolamine, or an analog thereof, in a pharmaceutically acceptable carrier. ... 11/23/06 - 20060264456 - Phosphorus-containing compounds & uses thereof each occurrence of G is independently —O—, —S—, —NR2— or (M)x; each occurrence of M is independently a substituted or unsubstituted methylene moiety, and any M-M′ moiety may be saturated or unsaturated; each occurrence of x is independently an integer from 1-6; and the other variables are as defined herein. ... 11/23/06 - 20060264455 - Use of huperzine for disorders Methods and compositions containing huperzine are used to alleviate pain and for the prevention and/or treatment of seizures and epilepsy. The invention is also directed to methods and compositions for using huperzine for the prevention and/or treatment of neuropathic pain and orthostatic hypotension. ... 11/23/06 - 20060264454 - Use of huperzine for neuropathic pain Methods and compositions containing huperzine are used to prevent and alleviate neuropathic pain. The invention is also directed to methods and compositions for using huperzine for the prevention and/or treatment of neuropathic pain and orthostatic hypotension. ... 11/23/06 - 20060264453 - Rapamycin formulations and methods of their use Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein. ... 11/16/06 - 20060258699 - Compounds for inhibiting ksp kinesin activity The present invention provides compositions comprising these compounds that are useful for treating cellular proliferative diseases or disorders associated with KSP kinesin activity and for inhibiting KSP kinesin activity. ... 11/16/06 - 20060258698 - Liquid formulations for treatment of diseases or conditions Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but ... 11/02/06 - 20060247265 - Therapies for treating disorders of the eye Disclosed is the use of an mTOR inhibitor for treatment of certain eye disorders. ... 10/26/06 - 20060241134 - Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility The invention relates to the combination of certain active compounds from the acid pump antagonist class and compounds which modify gastrointestinal motility. ... 09/28/06 - 20060217409 - Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof Compounds are provided that, by way of their selective neurotransmitter binding useful for the treatment of various neurological and psychological disorders, e.g., ADHD. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein. ... 09/21/06 - 20060211726 - Ascomycin derivatives for combination treatment with tazorotene A method is disclosed herein comprising administering a therapeutically effective amount of an ascomycin derivative topically in combination with tazarotene, wherein said method is effective in reducing adverse events associated with tazarotene. A method is also disclosed herein comprising administering a therapeutically effective amount of an ascomycin derivative topically in ... 09/21/06 - 20060211725 - Use This invention relates to a new use of a compound of the following formula (I) or (II) for the manufacture of a medicament for preventing and/or treating chronic rejection in a transplanted organ or tissue. ... 09/21/06 - 20060211724 - Hiv integrase inhibitors The present invention concerns the compounds having the formula (1), N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof wherein (a) or (b); A, together with the two carbons of the phenyl ring to which it is attached forms a monocyclic aryl or a monocyclic Het2; R1 is ... 09/14/06 - 20060205758 - Method for reducing the mortality rate A method for reducing the mortality rate in a patient comprising administering to the patient a therapeutically effective amount of a tiotropium salt. ... 09/14/06 - 20060205757 - 39-desmethoxyrapamycin, compositions and methods of use thereof The present invention relates to medical uses of 39-desmethoxyrapamycin. ... 09/14/06 - 20060205756 - Antitussives R2 represents a hydrogen atom, substituted or unsubstituted lower alkyl or the like] or a pharmaceutically acceptable salt thereof. ... 09/07/06 - 20060199834 - Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin The invention provides a purified oxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin (SDZ-RAD Isomer C), a chemical process for its preparation, as well as pharmaceutical compositions and packs containing SDZ-RAD Isomer C and methods for its use as an immunosuppressive, anti-inflammatory, antifungal, antiproliferative and antitumor agent. ... 09/07/06 - 20060199833 - Novel chemiluminescent compounds and their use The present invention relates to novel chemiluminescent compounds, to a method for synthesizing these compounds, to derivatives and conjugates comprising these compounds, to the use of these compounds or conjugates thereof in chemiluminescence based assays, especially in immunoassays. ... 09/07/06 - 20060199832 - Use of non-immunosupressive pipecolic acid derivatives for inducing chondrogenic differentiation A non-immunosuppressive pipecolic acid derivative having an affinity for FKBP-type immunophilins is provided for inducing chondrogenic differentiation. Composition containing such compounds is also disclosed. ... 08/31/06 - 20060194829 - Therapeutic materials and methods Disclosed are compositions and methods for treating or preventing mucositis by administering to the patient an FKBP ligand prior to, during, or after treatments commonly associated with the development of mucositis such as certain chemotherapies, radiation therapies, or combinations thereof, but in particular, administration of an mTOR inhibitor such as ... 08/31/06 - 20060194828 - Vitamin comprising pyroloquinoline quinone and use thereof It is an object of the present invention to clarify the biochemical role of pyrroloquinoline quinone (PQQ) in living bodies by identifying an enzyme that uses PQQ as a coenzyme in mammals and then by clarifying the oxidation-reduction reaction, with which PQQ is associated as a coenzyme in living bodies. ... 08/24/06 - 20060189643 - Novel heterocyclic compounds having anti-hbv activity This application relates to novel fused tricyclic thienopyridines of Formulas I and II, which useful for treating Hepatitis B infection and other diseases. This application also relates to pharmaceutical compositions comprising thienopyridines and to the use of such compositions to treat Hepatitis B and other diseases. ... 08/24/06 - 20060189642 - Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases The invention relates to the administration of roflumilast oral or intravenously and an anticholinergic agent selected from the group of an ipratropium, oxitropium or tiotropium salt for the treatment of respiratory diseases. ... 08/17/06 - 20060183766 - Orally bioavailable cci-779 formulations A CCI-779 oral dosage form is provided in which, after oral administration to a subject, the CCI-779 has a whole blood peak concentration (Cmax) of 5.4±1.8 ng/mL and an area under the curve (AUC) of about 66±about 22 ng-hr/ml and the sirolimus has a Cmax of 18.7±9.6 ng/mL and an ... 08/10/06 - 20060178392 - Cci-779 polymorph and use thereof The present invention provides CCI-779 polymorph Form II. This invention also provides processes for preparing CCI-779 polymorph Form II and pharmaceutical compositions including CCI-779 polymorph Form II. ... 08/10/06 - 20060178391 - Method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives The present invention is directed to a method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives. ... 08/03/06 - 20060173033 - Use of rapamycin and rapamycin derivatives for the treatment of bone loss The present invention relates to a new use of rapamycin and rapamycin derivatives. ... 08/03/06 - 20060173032 - Isolation and structure of cribrostatin 6 Cribrostatin 6, a dark blue cancer cell growth inhibiting constituent of the Republic of Maldives marine sponge Cribrochalina sp. has been isolated, and its structure (shown below) elucidated, based on a combination of RMS, high field (500 MHz, HMBC, and GOESY experiments) 15N, 1H- and 13C NMR, and X-ray crystal ... 08/03/06 - 20060173031 - Therapeutic agent for schizophrenia Provision of a pharmaceutical agent useful for the treatment of schizophrenia. As a solving means, a therapeutic agent for schizophrenia containing a 4-acylamino-5,6,7,8-tetrahydrofuro[2,3-b]quinoline derivative, an enantiomer thereof, an acid addition salt thereof or a hydrate or solvate thereof as an active ingredient is provided. ... 07/27/06 - 20060167035 - Quinoline derivative, its use, production and pharmaceutical agents containing the latter in which R1, R2, R3, X, Y, Z and A are indicated in the description and the claims, the use of the compounds of general formula A for treating various diseases as well as the production of compounds of general formula A. ... 07/27/06 - 20060167034 - Novel benzonaphthyridines in which R1, R2, R3, R4, R5, R6 and n have the meanings as indicated in the description, are novel effective PDE3/4 inhibitors. ... 07/20/06 - 20060160838 - Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases and diastereomers, tautomers, solvates, metabolites, and pharmaceutically acceptable salts thereof, wherein X, A, L and Y are as defined herein. Such compounds are useful in the treatment of immunoregulatory and respiratory diseases in mammals. Also disclosed are methods of using such compounds in the treatment of immunoregulatory and respiratory diseases ... 07/20/06 - 20060160837 - Rapamycin compounds in the treatment of neurofibromatosis type 1 The present invention is directed to methods for treating neurofibromatosis type 1 (NF1) using rapamycin, derivatives of rapamycin or prodrugs of rapamycin. The invention covers the treatment both of non-malignant fibromas, as well as a variety of tumors associated with cells that have mutations in the NF1 gene. ... 07/13/06 - 20060154953 - Amorphous tacrolimus and preparation thereof The present invention provides amorphous tacrolimus in a free drug particulate form. Also provided are methods for preparing amorphous tacrolimus, and a tablet containing amorphous tacrolimus. ... 07/13/06 - 20060154952 - Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation-and ummunologically-mediated diseases The present invention relates to pharmaceutical compositions comprising in combination rapamycin or a rapamycin derivative and a compound of formula I, e.g. useful for the treatment of inflammatory and immunologically-mediated diseases, including autoimmune diseases. ... 07/13/06 - 20060154951 - Quaternary antimuscarinic compounds for the treatment of bladder diseases The present invention relates to a method for treating bladder disease, including urinary incontinence, which involves intravesical administration of quaternary antimuscarinic compounds having longer duration of effect and fewer side effects than standard treatments. ... 07/13/06 - 20060154950 - Novel use of rapamycin and structural analogues thereof The use of rapamycin and its structural analogues for the preparation of a medicament for the therapeutic treatment of beta-thalassaemia is described. ... 07/06/06 - 20060148841 - Pharmaceutical composition comprising combination of non-alkaloid and alkaloid-based component for treating skeletal muscle spasm A medicinal composition that may include an effective amount of a non-alkaloid and an alkaloid-based skeletal muscle relaxant are provided. A method that includes administering the medicinal composition to a human in an amount effective to treat a muscle spasm is provided. The medicinal composition may include an alkaloid-based and ... 07/06/06 - 20060148840 - Pyrrolodihydroisoquinolines as pde10 inhibitors The invention relates to novel pyrrolodihydroisoquinoline derivatives, which are efficacious inhibitors of PDE10. ... 07/06/06 - 20060148839 - New pharmaceutical compositions based on anticholinergics and tace-inhibitors The present invention relates to novel pharmaceutical compositions based on anticholinergics and TACE (TNF alpha converting enzyme) inhibitors, processes for preparing them and their use in the treatment of respiratory diseases. ... 06/29/06 - 20060142322 - 2-alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9h-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents wherein R represents methyl ester or amide and R1 represents alkyl, aryl and heteroaryl moiety. ... 06/22/06 - 20060135550 - Rapamycin derivatives and the uses thereof in the treatment of neurological disorders These compounds are useful in treating neurological disorders or complications due to stroke or head injury, and as neuroprotective and neuroregenerative agents. ... 06/22/06 - 20060135549 - Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative,and inflammatory disorders These compounds are useful in treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders. The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents. ... 06/22/06 - 20060135548 - Processes for producing crystalline macrolides The present invention provides processes for crystallization of macrolides, specifically pimecrolimus and tacrolimus. ... 06/15/06 - 20060128740 - Tricyclic androgen receptor modulator compounds and methods This invention relates to non-steroidal tricyclic compounds that are modulators of androgen receptors and to methods for making and using such compounds. ... 06/15/06 - 20060128739 - Solvent free amorphous rapamycin An improved process for coating implantable medical devices utilizes a number of techniques for improving the stability of therapeutic agents contained within the coating. The stability of the therapeutic agents may be improved by creating substantially solvent-free, amorphous forms of the therapeutic agents. ... 06/01/06 - 20060116392 - Methods for treating anxiety disorders and related article of manufacture This invention provides a method for treating a subject afflicted with an anxiety disorder whose symptoms are exacerbated by the subject's exposure to a predetermined eliciting event, which method comprises administering to the subject a therapeutically effective amount of a protein synthesis inhibitor before, during the time, and/or after the ... 05/25/06 - 20060111386 - Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive disorder, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine ... 05/25/06 - 20060111385 - Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive disorder, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine ... 05/18/06 - 20060106050 - Thrombin receptor antagonists R1, R2, R3, R9, R10 and R11 are as defined in the specification; are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. ... 05/18/06 - 20060106049 - Histone deacetylase inhibitors and methods of use Disclosed are methods of treating an acute myeloid leukemia patient of cytogenetic subgroups having increased histone deacetylase recruitment by administering a histone deacetylase inhibitor to the patient. ... 05/18/06 - 20060106048 - Furoisoquinoline derivative and use thereof wherein A represents (1) a bond, (2) a group represented by the formula —CRa═CRb— (Ra and Rb each represent a hydrogen atom or C1-6 alkyl) and the like; R1 represents (1) cyano or (2) an optionally esterified or amidated carboxyl group; R2 represents (1) a hydrogen atom, (2) an optionally ... 05/04/06 - 20060094746 - Thieno[2,3-c] isoquinolines for use as inhibitors of parp wherein the constituent variables are as defined herein. The invention further provides methods for the use of the compounds disclosed herein. ... 05/04/06 - 20060094745 - Use of an mtor inhibitor in treatment of uterine leiomyoma The invention provides for the use of an mTOR inhibitor in the treatment or inhibition of fibroids. ... 05/04/06 - 20060094744 - Pharmaceutical dosage forms of stable amorphous rapamycin like compounds The present invention provides a pharmaceutical dosage form comprising stable amorphous rapamycin like compounds and a pharmaceutically acceptable excipient and methods of making the pharmaceutical dosage form. ... 05/04/06 - 20060094743 - Isoquinoline compounds and medicinal use thereof The present invention relates to an isoquinoline compound represented by the following formula (I) or (II), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease ... 04/20/06 - 20060084672 - Method for modification of y-secretase activity through inhibition of fkbp13 The present invention provides a method for modifying γ-secretase activity in a cell or in an organism by de-stabilizing presenilin through inhibition of Fkbp13. Inhibition of Fkbp13 de-stabilizes presenilin and prevents formation of a functional γ-secretase complex thus decreasing γ-secretase activity and concomitantly decreasing production of amyloid-β peptides. The invention ... 04/13/06 - 20060079544 - Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic The present invention relates to a method for the prevention or the treatment of alveolar pneumonia comprising administration of a therapeutically effective amount of an anticholinergic 1, medicaments for the prevention or treatment of alveolar pneumonia comprising one or more, preferably one anticholinergic 1, and methods for the preparation of ... 03/23/06 - 20060063794 - Method of attenuating graft rejection The invention provides a method of attenuating graft rejection in a patient undergoing an organ or tissue transplantation procedure. The inventive method involves administering FK778 using a dosing regimen that includes a period of customized administration to achieve or approximate a target whole blood trough level of FK778. The regimen ... 03/16/06 - 20060058335 - Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments wherein X− and the groups A, R, R1, R2, R3, R3′, R4, and R4′ have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof as medicaments. ... 02/23/06 - 20060040971 - Rapamycin polymorphs and uses thereof The present invention provides rapamycin polymorph Form II. This invention also provides processes for preparing rapamycin polymorph Form II and pharmaceutical compositions including rapamycin polymorph Form II. ... 02/16/06 - 20060035919 - Tetracylic immunomodulatory compounds The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly, the present ... 02/16/06 - 20060035918 - Use of tacrolimus (fk506) derivatives combined with beta2-agonists for the treatment of asthma A method for treating or prevent acute or chronic asthma is disclosed, comprising administering effect amounts of an FK506 derivative and a β2-agonist to a human being or an animal. A composition comprising an FK506 derivative and a β2-agonist as a combined preparation is also disclosed ... 02/09/06 - 20060030579 - Compounds for the treatment of proliverative processes The invention relates to the use of anticholinergics for preparing a pharmaceutical composition for the prevention and treatment of proliferative processes. ... 02/02/06 - 20060025435 - Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof Compounds are provided that, by way of their selective neurotransmitter binding useful for the treatment of various neurological and psychological disorders, e.g., ADHD. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein. ... 01/19/06 - 20060014778 - Pyrrolo(oxo)quinolines as 5ht ligands The present application provides pyrrolo(oxo)isoquinolines as modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose ... 01/19/06 - 20060014777 - Pyrrolo(oxo)isoquinolines as 5ht ligands or pharmaceutically acceptable salt forms thereof, wherein A, B, D, E, m, n, R3, R7, R8, R9, R10, R11 and X are described herein. ... 01/19/06 - 20060014776 - Antitumoral compounds wherein R1 and R2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, C2-C12 alkenylidene, substituted or unsubstituted C3-C12 alkynylidene and substituted or unsubstituted C2-C12 acyl. ... 01/12/06 - 20060009482 - Screening method for identifying compounds that selectively induce interferon alpha Methods for screening for compounds that selectively induce IFN-α production and methods for ameliorating conditions in a patient using a small molecule that selectively induces the production of IFN-α are disclosed. ... 01/05/06 - 20060004037 - Novel tricyclic compounds and related methods of treatment The invention provides novel lipid soluble forms of tricyclic antineoplastic compounds. These forms include salts, co-crystals, and solvates of the tricyclic antineoplastic compounds. The invention also provides novel pharmaceutical compositions comprising these novel lipid soluble forms and related methods of treatment. Compositions and methods of the invention are useful in ... 12/29/05 - 20050288319 - Ccr1 antagonists and methods of use therefor wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity. ... 12/29/05 - 20050288318 - Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics to processes for preparing the same and to their use in therapeutics. ... 12/22/05 - 20050282849 - Carboline derivatives useful in the treatment of cancer In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor ... 12/08/05 - 20050272760 - Use of pyridoindolone derivatives for the preparation of medicinal products for the preparation of medicinal products that are useful as anticancer agents. ... 12/08/05 - 20050272759 - Carboline derivatives useful in the inhibition of angiogenesis In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy ... 12/08/05 - 20050272758 - Antineoplastic combinations of cci-779 and rituximab This invention provides the use of a combination of CCI-779 and rituximab in the treatment of non-Hodgkin's lymphoma. ... 12/08/05 - 20050272757 - Process to prepare camptothecin derivatives and novel intermediate and compounds thereof New processes are disclosed for the preparation of camptothecin derivatives, such as, irinotecan and topotecan, as well as new intermediates and compounds related thereof. ... 12/08/05 - 20050272756 - Pyridopyrrolizine and pyridoindolizine derivatives Pyridopyrrolizine and pyridoindolizine derivatives are prostaglandin receptor antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma. ... 12/01/05 - 20050267143 - Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof The invention includes compositions comprising substantially purified pyrroloquinoline quinone, that are useful in methods for the treatment and prevention of cardiac injury caused by hypoxia or ischemia. The invention also includes methods for the treatment and prevention of cardiac injury comprising contacting a composition of the invention with a human ... 11/17/05 - 20050256149 - Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts Pharmaceutical compositions and kits comprising: (a) a tiotropium salt; and (b) a salmeterol salt having a solubility in water of 0.1 mg/mL or less, processes for preparing them, and their use in the treatment of respiratory complaints, asthma, and chronic obstructive pulmonary disease (COPD). ... 11/10/05 - 20050250805 - Pharmaceutical ointment formulations A pharmaceutical ointment composition is provided comprising (a) a therapeutically effective amount of one or more active pharmaceutical ingredients comprising one or more macrolide related immunosuppressants or pharmaceutically acceptable salts or esters thereof; (b) an ointment base; and (c) an effective amount of one or more skin penetration enhancers capable ... 11/10/05 - 20050250804 - Pharmaceutical gel formulations A pharmaceutical gel composition is provided comprising (a) a therapeutically effective amount of one or more active pharmaceutical ingredients comprising one or more macrolide related immunosuppressants or pharmaceutically acceptable salts or esters thereof; (b) one or more gel forming agents; and (c) an effective amount of one or more skin ... 11/10/05 - 20050250803 - Combination of dopamine agonists and monoamine reuptake inhibitors This invention is directed to pharmaceutical compositions and kits comprising (i) a dopamine agonist of the formula II as described in the specification, (ii) a monoamine reuptake inhibitor or pharmaceutically acceptable salt thereof; and optionally (iii) a pharmaceutically acceptable carrier. This invention further relates to methods of treatment using those ... 11/03/05 - 20050245561 - Anti-tumour polycyclic carboxamides This invention relates to polycyclic carboxamide compounds of the formula (I) with cytotoxicity, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly I the treatment and/or prophylaxis of cellular proliferative disorders such a cancer. ... 10/27/05 - 20050239813 - Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases The invention provides ophthalmic compositions and methods treating the symptoms of ocular allergies. The principle active ingredient in these compositions and methods is macrolide compound, such as tacrolimus, ascomycin and rapamycin and their derivatives. Optimal concentrations and dosing regimens are provided. ... 10/20/05 - 20050234087 - Process for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies Methods for the synthesis of regiospecific rapamycin 42-hemiesters and regiospecific FK506 32-esters with dicarboxylic acids is described. The methods involve catalyzing the reaction between a rapamycin or a FK-506 and a dicarboxylic anhydride or a bifunctional activated ester of dicarboxylic acid with a lipase. ... 10/20/05 - 20050234086 - Proline cci-779, production of and uses therefor, and two-step enzymatic synthesis of proline cci-779 and cci-779 Methods for the synthesis of CCI-779 and proline-CCI-779 are described, including a method involving lipase-catalyzed acetylation of 42-hydroxy of rapamycin with a vinyl ester of 2,2-bis(hydroxymethyl) propionic acid in an organic solvent followed by deprotection. Also provided are products containing proline-CCI-779 and uses thereof. ... 10/13/05 - 20050228010 - Antidepressant azahetorocyclylmethyl derivatives of 7,8-dihydro-6h-5-oxa-1-aza-phenanthrene useful for the treatment of such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized ... 10/13/05 - 20050228009 - Antidepressant piperidine derivatives of heterocyclefused benzodioxans are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, ... 10/06/05 - 20050222192 - Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics R4 and R5 are identical or different and each independently represent a hydrogen or halogen atom or a hydroxyl, hydroxymethyl, (C1-C4)alkyl, trifluoromethyl, C1-C4)alkoxy, (C1-C4)alkoxycarbonyl or cyano group. Preparation process and application in therapeutics. ... 10/06/05 - 20050222191 - Solution formulations of sirolimus and its analogs for cad treatment Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed ... 09/29/05 - 20050215580 - Tetrahydrocarboline compounds as anticancer agents Tetrahydrocarboline compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the tetrahydrocarboline compounds, either alone or in combination with at least one ... 09/22/05 - 20050209266 - Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use The invention describes novel nitrosated and/or nitrosylated rapamycin compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated rapamycin compound, and, optionally, at least one nitric oxide donor compound. The invention also provides novel compositions comprising at least one rapamycin compound and at least one nitric oxide donor compound ... 09/22/05 - 20050209265 - Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug Bifunctional molecules and methods for their use are provided. The subject bifunctional molecules are conjugates of a drug moiety and a pharmacokinetic modulating moiety, where these two moieties are optionally joined by a linking group. The bifunctional molecules are further characterized in that they exhibit at least one modulated pharmacokinetic ... 09/22/05 - 20050209264 - Tetrahydro-beta-carboline compounds and use thereof wherein x, y and z are each independently an integer of 0 to 4 and R is selected from the group consisting of H, alkyl, aryl and heterocyclic moiety wherein the alkyl, aryl and heterocyclic moiety are optionally substituted with a member selected from the group consisting of halogen, alkoxy ... 09/08/05 - 20050197357 - Anticholinergics which may be used as medicaments as well as processes for preparing them wherein A, X−, and the groups R1, R2, R3, R4, R5, R6 and R7 may have the meanings given in the claims and in the specification, processes for preparing them and their use as pharmaceutical compositions. ... 09/08/05 - 20050197356 - Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents This invention relates, in part, to the use of non-immunosuppressive immunophilin ligands, such as meridamycin, in treating neurological disorders. ... 09/01/05 - 20050192311 - Process for production of o-alkylated rapamycin derivatives (where R denotes alkyl, arylalkyl, hydroxyalkyl, alkoxyalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl, acylaminoalkyl, or aryl.) This process is capable of producing O-alkylrapamycin derivative efficiently owing to improvement in reaction yields for O-alkylation. ... 09/01/05 - 20050192310 - Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 Fused heterotricyclic compounds, methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions containing such compounds. ... 08/25/05 - 20050187241 - Method of inhibiting choroidal neovascularization The present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and/or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening of potential agents as anti-angiogenesis and anti-CNV agents. ... 08/18/05 - 20050182084 - Method for treating erectile dysfunction Macrolide compound (I) is provided for treating or preventing erectile dysfunction, which is, for example, induced by or secondary to diseases, alcoholism, aging, arterial insufficiency, venous leakage, hormonal insufficiency, drug use, surgery, chemotherapy or radiation, particularly, for preventing or treating an erectile dysfunction of mammals. ... 08/11/05 - 20050176750 - Substituted 4h-chromens, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof The present invention is directed to substituted 4H-chromenes, 2H-chromenes, chromans and analogs thereof, represented by the general Formula (I) wherein R5, A, B, X, Y, Z and dotted lines are defined herein. The present invention also relates to the discovery that compounds having Formula (I) are activators of caspases and ... 08/04/05 - 20050171137 - Biologically active peptides and compositions, their use wherein Y, n, R1, R2, R3, R6, R7, R70, R71, R72, R74, and R75 are as defined in the specification. ... 07/28/05 - 20050165042 - Fused tricyclic heterocycles useful for treating hyper-proliferative disoroders This invention relates to a novel fused tricyclic heterocycle of the formula (Ia, Ib) and its use for the treatment of hyper-proliferative disorders. ... 07/21/05 - 20050159441 - Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage The invention relates to an apparatus comprising a closure-cap and a container in the form of a two-chamber cartridge in which an active ingredient and a solvent can be stored separately until the apparatus is used in a nebuliser, as well as an active substance concentrate in which the active-substance ... 07/14/05 - 20050154006 - Pharmaceutical compositions based on a scopineester and nicotinamide derivatives wherein X− has the meanings specified in the description and claims and one ore more, preferably one nicotinamide derivative, processes for preparing them and their use in the treatment of respiratory diseases. ... 07/14/05 - 20050154005 - Methods to modulate conditions mediated by the cxcr4 receptor The present invention is drawn to novel antiviral compounds, pharaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines wihich have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors ... 06/30/05 - 20050143412 - Methods of indirectly stimulating the vagus nerve with an electrical field Controlled cessation of heart beat during coronary bypass surgery and other cardiac surgeries on a beating heart improves surgical technique, and is achieved typically by electrical stimulation of the vagus nerve and administration of a combination of drugs. ... 06/30/05 - 20050143411 - Method for treating pulmonary disease Methods for treating or preventing airflow obstructions, such as the obstruction induced by cigarette smoke, comprising administering macrolide compounds, such as the FK506 substance and its related compounds, are provided. Compositions containing such compounds are also disclosed. ... 06/30/05 - 20050143410 - Novel crystalline anhydrate with anticholinergic efficacy The invention relates to a new crystalline anhydrate of tiotropium bromide, processes for preparing it and its use for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma. ... 06/30/05 - 20050143409 - Regimen for the administration of rifamycin-class antibiotics The invention features an ascending dose regimen for the administration of rifamycin-class antibiotics. The dosing regimen can be used to treat bacterial infections and diseases related to infection. ... 06/23/05 - 20050137220 - Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors A method is described for inhibiting mitogen activated protein kinase-activated protein kinase-2 in a subject in need of such inhibition, where the method involves administering to the subject a beta-carboline MK-2 inhibiting compound, or a pharmaceutically acceptable salt thereof. ... 06/16/05 - 20050131010 - Synthesized gamma-carbolines and the prodrug and salts thereof, wherein R may be a hydroxyl or other pendent group and Ar is an aryl. The compositions may be adapted for the treatment of neurodegenerative diseases. Further, the compositions may be adapted as a pharmaceutical such as an antipsychotic pharmaceutical, an antibiotic pharmaceutical, an ... 06/16/05 - 20050131009 - Urea substituted imidazoquinolines Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and ... 06/16/05 - 20050131008 - 42-o-alkoxyalkyl rapamycin derivatives and compositions comprising same 42-O-alkoxyalkyl derivatives of rapamycin having biological activity are described. Compositions and delivery devices comprising the 42-O-alkoxyalkyl rapamycin derivatives are also disclosed. ... 06/16/05 - 20050131007 - Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof The invention relates to a process for preparing new tiotropium salts, these new tiotropium salts as such, pharmaceutical formulations containing them and their use for preparing a medicament for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma. ... 06/16/05 - 20050131006 - Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy The invention provides a method for determining the activation status of receptor tyrosine kinase (RTK) pathways in either cell samples or patient samples by measuring receptor dimerization and relative amounts of protein-protein complexes or activated effector proteins that are characteristic of an RTK pathway. The invention also provides a method ... 06/09/05 - 20050124647 - Tricyclic derivatives of indole with antiangiogenic activity useful for treating tumors, particularly mammary carcinoma and colon carcinoma. ... 06/09/05 - 20050124646 - Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same to a process for their production, to a pharmaceutical composition containing the same and to a use thereof. ... 06/09/05 - 20050124645 - Methods and compositions for increasing cd4lymphocyte immune responsiveness Compositions and methods are provided for the treatment of infections by microbes associated with a latent infection. ... 06/09/05 - 20050124644 - Medical product The invention discloses a medical product for use in a treatment of respiratory disorders, and comprises a metered dose of a tiotropium dry powder formulation, directly loaded and sealed into a container made to act as a dry high barrier seal to prevent the capture and ingress of moisture into ... ### FreshPatents.com Support |